resbiotic Nutrition has completed a $14.5 million funding round, including an $8 million Series A led by Sororibus Capital and Biostack Ventures. The new funding will fuel the expansion of the company’s product lineup, support rapid growth in retail and e-commerce channels, and strengthen its business-to-business ingredient and formulation offerings.
At the center of resbiotic’s approach lies the Gut-X Axis concept, which links gut microbiome function to health outcomes in distant organ systems. The company’s flagship supplement, resB Lung Support, represents the first probiotic clinically tested to target the gut–lung connection and improve respiratory wellness.
Building on that success, resbiotic will introduce formulations aimed at metabolic balance, women’s health, and bone strength, all backed by rigorous preclinical research and human trials.
resbiotic’s vertically integrated research and development model combines in-house formulation capabilities with clinical scientists and physician oversight. This structure accelerates product innovation, ensures consistency, and allows rapid iteration in response to trial results. As the pipeline grows, the company plans to add new postbiotic and prebiotic ingredients that address specific chronic health challenges.
The demand for resbiotic’s proprietary microbiome ingredients is rising among supplement manufacturers and food brands. The company’s B2B division provides custom ingredient blends and turnkey formulation services, creating partnerships that extend resbiotic’s scientific platform into new consumer products.
On the consumer front, resbiotic products are now stocked in Walmart stores nationwide and available through the company’s direct-to-consumer website. This dual-channel strategy ensures broad access while supporting data-driven marketing to reach people seeking evidence-based supplements.
How the funding will be used: Looking ahead, resbiotic will deploy its new funding to accelerate clinical studies, expand manufacturing capacity, and forge additional retail partnerships. With growing consumer interest in microbiome science, the company aims to set a new standard for supplements that deliver measurable, system-wide health benefits.
KEY QUOTES:
“With res, we are setting a new standard in the supplement industry – products that are not only rooted in rigorous science but also accessible to people everywhere. By combining robust preclinical testing and clinical trials at the product level with a vertically integrated R&D model, we ensure our formulations deliver real, measurable benefits. This funding enables us to expand our Gut-X Axis portfolio, deepen our retail partnerships, and meet growing consumer demand for evidence-based health solutions.”
Dr. C. Vivek Lal, Founder and CEO
